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Abstract
Background: Sonic hedgehog (SHH) plays critical roles in cell growth and development. Tumor cells express SHH,
which can promote cell proliferation and epithelial-to-mesenchymal transition. However, the autocrine SHH
pathway has not been described in gastric cancer. The aim of this study was to explore molecular mechanisms
underlying autocrine SHH signaling in gastric cancer cells.
Methods: SHH expression was assessed using immunohistochemistry and the results were compared with
clinicopathologic parameters, including survival. Using gastric cancer cell lines, we measured SHH mRNA and
protein expression, and studied the effects of SHH signaling on cell proliferation and SHH secretion. We also
studied the effects of an inhibitor of PLC-γ1 on phosphorylation of phospholipase Cγ1 and extracellular signal-
regulated kinases (ERK)1/2.
Results: SHH protein expression in gastric cancer tissue was significantly higher compared with that in normal gastric
tissue (P < 0.001), and the increased expression was significantly associated with pT staging (P = 0.004), pN staging
(P = 0.018), pM staging (P = 0.006), and pTNM staging (P < 0.001). In multivariate analyses, overall survival in gastric cancer
was significantly shorter in cases with high SHH expression (HR = 1.734, 95 % CI: 1.109–2.713, P = 0.016). The AGS and
SGC-7901 gastric cancer cell lines expressed SHH mRNA and protein. In these cell lines, SHH promoted carcinogenesis
through activation of the PLCγ1-ERK1/2 pathway, resulting in increased cell proliferation and survival.
Conclusions: Increased SHH expression is associated with shorter survival in gastric cancer patients, and SHH could
represent a useful biomarker or therapeutic target for this disease.
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Background
Gastric cancer (GC) is the fifth most common form of
carcinoma and the second leading cause of cancer-
related mortality worldwide [1]. It is estimated that there
are approximately 400,000 new cases in China annually,
comprising approximately 43 % of the global total [2].
Despite advances in chemotherapy and surgery, the
prognosis of patients with advanced GC remains poor.
For instance, the 5-year survival rate is only 4 % for
stage IV GC [3]. Targeted molecular therapy provides
greater specificity and selectivity than traditional treat-
ments, decreasing the likelihood of drug resistance and
chemotherapy-associated side effects [4]. Despite their
superior efficacy against many tumors, the effects of tar-
geted drugs on GC remain unsatisfactory. Therefore, it
is necessary to further understand the molecular mech-
anism underlying GC development and to design new
targeted drugs for improving the prognosis and treat-
ment of GC patients.
The Hedgehog signaling pathway plays a critical role
in stem cell maintenance and the specification of
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patterns related to cell growth and differentiation during
embryonic development [5–7]. Hedgehog was first iden-
tified as a secreted protein in Drosophila melanogaster
[8, 9]. Hedgehog has three mammalian counterparts:
Sonic hedgehog (SHH), Indian hedgehog, and Desert
hedgehog. The SHH signaling pathway is activated by
SHH binding to the Patched (Ptch)-Smoothened (Smo)
membrane-receptor complex. Upon activation in verte-
brates, Smo promotes nuclear translocation of the Glis
family of transcription factors (Gli1, Gli2, and Gli3) that
subsequently activates target gene expression [6, 10–12].
Recent studies have shown that SHH signaling is abnor-
mally activated in neuroblastoma, colorectal cancer, basal
cell cancer, medulloblastoma, prostate cancer, ovarian can-
cer, pancreatic cancer, and other forms of cancer [10, 13].
Some studies have suggested that SHH signaling activation
could contribute to carcinogenesis [14–17]. Several studies
confirmed that SHH pathway activation is associated with
poorly differentiated and aggressive types of GC [18–20].
Therefore, an increased understanding of SHH signaling
in carcinogenesis could provide novel insights into GC
treatment. Liu et al [21]. reported that autocrine SHH
signaling enhanced myeloma cell proliferation and pro-
tected cells against chemotherapy-associated spontan-
eous and stress-induced apoptosis. Few studies have
explored the mechanism of autocrine SHH signaling on
cell proliferation in GC.
In this study, we performed in vitro experiments to de-
termine the effects of autocrine SHH signaling on GC
proliferation. Moreover, we examined the expression of
SHH in GC tissues and adjacent non-tumor tissues. Fur-
thermore, we evaluated the association between SHH




Ethical approval for human subjects was obtained from
the Institutional Review Board of the First Affiliated
Hospital of Sun Yat-Sen University (FAHSYSU), and writ-
ten consent was obtained from each patient. GC paraffin-
embedded tissues were obtained from Department of
Pathology. Briefly, samples from 117 GC patients, who re-
ceived surgical treatment at FAHSYSU between 2004 and
2005, were collected and confirmed as GC, and then made
available for this study. Follow-ups were terminated until
December 2013.
Fresh tumor samples from resection specimens were
collected from patients with primary GC who were
treated by gastric surgery without radiotherapy or
chemotherapy before surgical resection at FAHSYSU in
2014 (N = 30). All excised tissues were frozen immedi-
ately in liquid nitrogen and then stored at -80 °C.
The use of all tissue blocks and serum samples for this
study was approved by the Institutional Ethics Review
Board of FAHSYSU.
Cell culture and reagents
Human GC cell lines AGS, SGC-7901, MGC823, HGC-
27 and MKN-1 were obtained from the Cell Bank of
Chinese Academy of Medical Science (Shanghai, China).
These cells were cultured in Dulbecco’s modified Eagle’s
medium containing 10 % fetal bovine serum (Invitrogen
Life Technology, Carlsbad, CA), penicilin (100 U/mL),
and streptomycin (100 mg/mL). Recombinant SHH was
purchased from R&D Systems, Minneapolis, MN.
Collection of condition medium
The GC cells were grown in 15 cm petri dishes until
~80 % confluency. The medium was aspirated off, and
monolayer was washed three times with PBS, once with
serum-free RIMP-1640, and then replenished with
serum-free RIMP-1640. After 48 h incubation, medium
was collected, filtered and stored at -80 °C until use.
Immunohistochemical (IHC) staining
For IHC, deparaffinized sections were pretreated with
10 mM sodium citrate buffer for antigen unmasking
(pH 6.0, boiling temperature, 30 min), blocked in normal
serum (Vectastain ABC kit, Vector Laboratories, Inc.
Burlingame, CA), incubated with primary antibodies at
4oC overnight, rinsed, and incubated with secondary
antibody (Vectastain ABC kit). Signals were amplified
using Vectastain ABC kit per manufacturer’s instruction.
Targeted protein was visualized using diaminobenzidine
as substrate. The results were interpreted by two inde-
pendent pathologists who were blinded to the specific
diagnosis and prognosis for each case, and were scored
by a semi-quantitative method in which staining of more
than 10 % of the tumor cells were considered positive.
The staining intensity was scored as “negative”,“weak
staining”, “moderated staining” and “strong staining”.
Low SHH expression was determined by negative and
weak staining, and high SHH expression was determined
by moderate and strong staining.
Western blot
Total protein was extracted with cell lysis buffer and the
protein concentration was quantified using an Enhanced
BCA Protein Assay Kit. Protein was separated by 8–10 %
SDS-PAGE and electrotransferred to PVDF membranes
(Millipore, Billerica, MA, USA). The membrane was
blocked for 1 h with 5 % BSA in TBS-T, and probed with
corresponding primary antibodies overnight at 4uC,
followed by incubation with rabbit and mouse radish
peroxidase-coupled secondary antibodies for 1 h.
Specific bands were detected using the enhanced
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chemiluminescence reagent (Millipore, Billerica, MA,
USA) on autoradiographic film. The primary antibodies
used were as follows: anti-SHH, SHH-neutralization anti-
body (Abcam, USA), anti-PLCγ1, anti-phosphorylated
PLCγ1, anti-ERK1/2, anti-phosphorylated ERK1/2 (Cell
Signaling Technology, Danvers, MA, USA), anti-GAPDH
(Proteintech, Wuhan, China), PLCγ1 inhibitor (U73122,
Sellock, Shanghai, China).
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was isolated using RNA plus reagent
(TaKaRa, Japan). Complementary DNA was prepared
using oligodT primers according to the protocol sup-
plied with the Primer Script TM RT Reagent (TaKaRa,
Japan). Expression of SHH was determined by quantita-
tive real-time PCR using Power SYBR green PCR master
mix (Applied Biosystems).
Proliferation assay
Cell counting Kit-8 (CCK-8) assay was used to detect
cell proliferation. In brief, cells were seeded onto 96-well
cell culture cluster plates (KeyGene, Nanjing, China) at a
density of 2 × 103 cells/well in 100 μL culture after treat-
ing with CM in the presence or absence of SHH-NA,
rhSHH and U73122for 48 h. Then, 10 μL CCK-8 re-
agents (Dongjido, Japan) were added to each well for 2 h
incubation at 37 °C according to the manufacturer’s
instructions. The absorbance was read at the wavelength
of 450 nm in an automated plate reader. The experi-
ments have been repeated at least three times.
Enzyme-linked immunosorbent assays (ELISA)
The secreted SHH levels were detected by ELISA. One
hundred microliters of cell supernatant was used for the
SHH assay using an ELISA kit (Lifespan, BioSciences,
USA). Briefly, a total of 100 μl per well of condition
medium and standard solution were added to antibody
coated 96 well plates and incubated for 2 h at room
temperature, followed by addition of biotin-conjugated
polyclonal antibody specific for SHH and incubation for
one hour. The plate was then washed and incubated
with avidin conjugated to HRP (Lifespan BioSciences,
USA) for 1 h. Color was developed using TMB substrate
(eBioscience), stoped by adding sulfuric acid and mea-
sured using a plate reader (M200 Pro, Tecan) at a wave-
length of 450 nm.
Statistical analyses
The SPSS ver 18.0 (SPSS Inc, Chicago, IL) was used for
analysis of the data. The relationship between SHH ex-
pression and features of tumor progression were ana-
lyzed using the Chi-square and the Fisher’s exact tests.
Kaplan–Meier survival curves were constructed and the
log-rank test was carried out in univariate analysis.
Fig. 1 SHH protein and mRNA levels are increased in GC tissue. a SHH protein expression was analyzed using western blot in tumor (T) and
normal (N) gastric tissues in 4 typical samples. b Scatter plots of the densitometrical data show the distribution of SHH expression in tumor and
normal gastric tissues (n = 30). c SHH gene expression was analyzed using qRT-PCR in tumor and normal gastric tissues (n = 30). d Serum SHH
was analyzed using ELISA in GC patients (n = 10) and control subjects (n = 10)
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Multivariate analysis was performed using Cox’s propor-
tional hazards model. A P-value of 0.05 was considered
to be statistically significant for all analyses.
Results
Increased levels of SHH in peripheral blood and tumor
tissue of GC patients
SHH protein expression in GC tissue and adjacent non-
tumor tissue was analyzed using western blot in a cohort
of 30 patients. We found that compared with tumor tis-
sues, 9 patients (9/30) have low SHH expression in
tumor tissues, and 21 patients (21/30) have high SHH
expression in tumor tissues. SHH protein expression
was significantly higher in tumor tissue compared with
that in non-tumor tissue (Fig. 1a & b) (P = 0.013). SHH
expression at the mRNA level in GC tissue and adjacent
non-tumor tissue was analyzed using qRT-PCR in a co-
hort of ten patients. SHH gene expression was signifi-
cantly higher in most tumor tissues (Fig. 1c) (P = 0.002).
SHH mRNA expression was normalized to that of
GAPDH mRNA, which served as a control for the input
cDNA.
The increased SHH expression observed in GC tissue
prompted us to evaluate SHH levels in GC patient
blood. We quantified serum SHH concentrations in
samples from 10 GC patients and 10 age-matched con-
trols using ELISA. Serum SHH levels were higher in GC
patients compared with those of age-matched health
controls (Fig. 1d) (P = 0.004).
Association between SHH protein expression and
clinicopathologic factors in GC patients
SHH potentially contributes to GC progression, and in-
creased SHH expression could be associated with more ad-
vanced stages of the disease. Immunohistochemistry was
performed to evaluate SHH protein expression in 117 GC
tissue samples (Fig. 2). Weak staining (score: 1+) was ob-
served in 46.15 % of patients (54/117), moderate staining
(score: 2+) was observed in 30.77 % of patients (36/117),
strong staining (score: 3+) was observed in 10.26 % of pa-
tients (12/117) and negative staining (score: 0) was ob-
served in 12.82 % of patients (15/117). Furthermore, as
shown in Table 1, a chi-square test suggested that high
SHH expression (scores of 2+ and 3+) in GC tissue samples
significantly correlated with advanced distant metastasis
(pM staging, 20.8 % vs 4.3 %, P = 0.006), and advanced
TNM staging (89.6 % vs 55.1 %, P < 0.001). Interestingly,
low expression of SHH was significantly associated with
advanced tumor invasion (pT staging, 85.5 % vs 62.5 %,
P = 0.004), increased lymph node metastasis (pN sta-
ging, 89.9 % vs 72.9 %, P = 0.017). However, there were
no statistically significant relationships between SHH ex-
pression and other clinicopathological variables such as age
(P = 0.479), gender (P = 0.444), tumor location (P = 0.578),
tumor size (P = 0.223), histological type (P = 0.357),
degree of differentiation (P = 0.232), and Bormann
classification (P = 0.924).
Correlation between SHH protein expression and the
prognosis of GC patients
We next evaluated the relationship between SHH expres-
sion and GC prognosis. For all patients in the study, the
follow-up period ranged from 3 to 114 months, with a
mean survival time of 47.6 (47.571 ± 3.590) months and a
5-year overall survival (OS) rate of 25.64 %. We used a
Kaplan-Meier plot to compare survival between patient
groups with low SHH expression (N = 69) and high SHH
expression (N = 48). High SHH tumor expression was as-
sociated with a poor prognosis (Fig. 3, P = 0.033). Median
survival time was 53.5 (53.517 ± 4.602) months in the low
SHH expression group and 38.5 (38.542 ± 5.354) months
in the high SHH expression group. The 5-year OS rate
was 30.43 % in the low SHH expression group and
16.67 % in the high SHH expression group.
As shown in Table 2, a univariate analysis showed that
gender (HR = 0.580, 95 % CI, 0.360–0.934, P = 0.025), age
Fig. 2 IHC staining of SHH protein in GC tissue. SHH protein expression
was evaluated in GC tissue samples and classified as negative, weak,
moderate, or strong. Magnification: ×200 (I) and × 400 (II)
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(HR = 1.682, 95 % CI, 1.071–2.641, P = 0.024), differenti-
ation degree (HR = 0.623, 95 % CI, 0.389–0.997, P = 0.049),
pN staging (HR = 1.652, 95 % CI, 1.221–2.234, P = 0.001),
pM staging (HR = 3.017, 95 % CI, 1.536–5.926, P =
0.001), and SHH expression (HR = 1.776, 95 % CI,
1.119–2.820, P = 0.015) were significantly associated
with GC prognosis. Furthermore, a multivariate analysis
demonstrated that SHH expression status was an inde-
pendent prognostic predictor in GC patients (HR = 1.734,
95 % CI, 1.109–2.713, P = 0.016).
Table 1 Relationship between SHH expression and clinicopathologic characteristics in GC patients
Characteristic N SHH Expression
Low(n = 69) High(n = 48) Χ2 Value P value
Gender
Male 71 41 (59.42 %) 30 (62.50 %) 0.113 0.444
Female 46 28 (40.58 %) 18 (37.50 %)
Age (years)
<60 y 74 43 (62.38 %) 31 (64.58 %) 0.062 0.479
≥ 60 y 43 26 (37.62 %) 17 (35.42 %)
Location
Proximal 14 10 (14.49 %) 4 (8.33 %) 1.973 0.578
Middle 18 10 (14.49 %) 8 (16.67 %)
Distal 59 32 (46.38 %) 27 (56.25 %)
More than 2 26 17 (24.64 %) 9 (18.75 %)
Tumor size
<5 cm 67 37 (53.62 %) 30 (62.50 %) 0.911 0.223
≥ 5 cm 50 32 (46.38 %) 18 (37.50 %)
Histologic type
Adenocarcinoma 98 59 (85.51 %) 39 (81.25 %) 0.377 0.357
Others 19 10 (14.49 %) 9 (18.75 %)
Bormann classification
1 6 4 (5.80 %) 2 (4.17 %) 0.476 0.924
2 24 15 (21.74 %) 9 (18.75 %)
3 69 39 (56.52 %) 30 (62.50 %)
4 18 11 (15.94 %) 7 (14.58 %)
Differentiation grade
Well 26 19 (27.54 %) 7 (14.58 %) 2.924 0.232
Moderately 66 48 (69.56 %) 40 (83.33 %)
Poorly 25 2 (2.90 %) 1 (2.08 %)
pT staging
T1–2 28 10 (14.49 %) 18 (37.50 %) 8.231 0.004
T3–4 89 59 (85.51 %) 30 (62.50 %)
pN staging
N0 20 7 (10.14 %) 13 (27.08 %) 5.731 0.017
N1-3 97 62 (89.86 %) 35 (72.92 %)
pM staging
M0 104 66 (95.65 %) 38 (79.17 %) 7.789 0.006
M1 13 3 (4.35 %) 10 (20.83 %)
pTNM staging
I–II 36 31 (44.93 %) 5 (10.42 %) 15.827 <0.001
III–IV 81 38 (55.07 %) 43 (89.58 %)
Ertao et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:63 Page 5 of 10
SHH expression in GC cell lines
We determined that GC patients have a higher SHH
concentration in the blood compared with that of
controls. Therefore, we hypothesized that autocrine
SHH signaling is required for gastric carcinogenesis.
In this regard, we examined the expression of SHH
signaling pathway related factors (SHH, PTCH1,
SMO, GLI1) in 5 GC cell lines, including AGS, SGC-
7901, BGC-823, HGC-27 and MKN-1 using western
blot and qRT-PCR. By Western blot and qRT-PCR,
we found that SHH is differentially expressed, with
the highest level in AGS, medium level in SGC-7901
and HGC-27, and the lowest level in BGC-823 and
MKN-1 (Fig. 4a & b). We also evaluated SHH
concentration in conditioned media (CM) using
ELISA (Fig. 4c). Based on initial analyses, we selected
AGS and SGC-7901 for further experiments, as these
displayed activated SHH signaling.
Autocrine SHH signaling promotes GC cell proliferation
Next, we determined whether the activity of autocrine
SHH is positively associated with cell activation in GC.
Cells treated with recombinant human SHH (rhSHH) dis-
played increased cell activity in AGS (Fig. 5a, top panel)
and SGC-7901 (Fig. 5a, bottom panel) cells. Treatment
with an SHH neutralizing antibody (SHH-NA) signifi-
cantly decreased the proliferation of AGS (Fig. 5b, top
panel) and SGC-7901 (Fig. 5b, bottom panel) cells. Spe-
cific concentrations of rhSHH (50 ng/ml) and STIP-NA
(30 ng/ml) were used for further experiments.
To determine whether a similar mechanism also ex-
ists in GC, AGS and SGC-7901 cells were treated with
their respective CM in the presence or absence of
SHH-NA. The proliferation of AGS and SGC-7901
cells in their respective CM was significantly higher
than that in basal media (BM) (Fig. 5c). SHH-NA treat-
ment moderately decreased CM-induced cell prolifera-
tion in AGS cells (Fig. 5c, top panel) and significantly
decreased proliferation in SGC-7901 cells (Fig. 5c, bot-
tom panel), suggesting that a functional extracellular
autocrine mechanism mediated by secreted SHH exists
in GC cells.
Autocrine SHH signaling promotes cell proliferation
through the PLCγ1-ERK1/2 pathway
To explore the underlying mechanism of autocrine SHH
signaling in GC, we analyzed the downstream signaling
pathways modulated by the PLCγ1-ERK1/2 pathway
Fig. 3 High SHH protein expression correlates with poor GC
prognosis. Patients with higher SHH expression displayed a lower
survival rate compared with that of patients with lower
expression (P = 0.033)
Table 2 Univariate and multivariate analyses of clinicopathological factors for overall survival in GC patients
Variables Univariate analysis Multivariate analysis
HR 95 % CI P value HR 95 % CI P value
Lower Upper Lower Upper
Gender 0.580 0.360 0.934 0.025 0.576 0.371 0.895 0.014
Age 1.682 1.071 2.641 0.024 1.634 1.066 2.505 0.024
Tumor location 0.972 0.736 1.285 0.844
Tumor size 1.045 0.636 1.717 0.862
Histologic type 0.890 0.686 1.155 0.380
Bormann classification 1.089 0.811 1.461 0.571
Differentiation grade 0.623 0.389 0.997 0.049 0.602 0.377 0.962 0.034
pT staging 0.742 0.274 2.007 0.557
pN staging 1.652 1.221 2.234 0.001 1.682 1.365 2.072 <0.001
pM staging 3.017 1.536 5.926 0.001 3.003 1.582 5.701 0.001
pTNM staging 1.272 0.488 3.315 0.622
SHH expression 1.776 1.119 2.820 0.015 1.734 1.109 2.713 0.016
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using western blot. We observed increased PLCγ1 and
ERK1/2 phosphorylation 15 min after rhSHH treatment,
which peaked between 30 and 60 min in both cell lines
(Fig. 6a). These data demonstrated that autocrine SHH
signaling could activated PLCγ1 and ERK1/2 in a time
dependent fashion.
To determine whether the autocrine SHH-mediated cell
proliferation was activated through the PLCγ1-ERK1/2
pathway, cells were treated with their respective CM in
the presence or absence of SHH-NA. In both cell lines,
PLCγ1 and ERK1/2 phosphorylation was increased follow-
ing CM treatment. In the presence of SHH-NA, CM did
not promote PLCγ1 and ERK1/2 phosphorylation (Fig. 6b).
That demonstrated that physiological dose of SHH also
could activate PLCγ1 and ERK1/2.
To further investigate the role of PLCγ1 in GC cell
proliferation, we treated GC cells with a PLC inhibitor,
U73122, to determine the effect on GC cell viability.
Compared with the control group (DMF only), U73122
significantly inhibited AGS (Fig. 6c) and SGC-7901
(Fig. 6d) cell proliferation at concentrations of 1 μM and
5 μM, respectively.
We next evaluated whether the PLCγ1-ERK1/2 signaling
pathway was responsible for the rhSHH-induced increase
in cell proliferation. Cells were treated with DMF or 5 μM
of U73122 overnight followed by a 60 min exposure to
Fig. 4 SHH expression in GC cell lines. a Expression of Hedgehog signaling pathway-related proteins was analyzed using western blot in GC cell
lines. b SHH gene expression was analyzed using qRT-PCR. c SHH secretion was analyzed using ELISA
Fig. 5 Autocrine SHH signaling affects cell proliferation in cultured GC cells. a Effect of Recombination Human SHH (rhSHH) treatment on
proliferation of AGS (top panel) and SGC-7901 (bottom panel) cells. b GC cell proliferation in response to SHH-neutralizing antibody (SHH-NA) in
AGS (top panel) and SGC-7901 (bottom panel). c AGS (top panel) and SGC-7901 (bottom panel) cell proliferation under Basic Medium (BM) and
Condition Medium (CM) with or withoutSHH-NA. Mean ± SEM, t-test, *P < 0.05, **P < 0.01,***P < 0.001
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rhSHH. Again, rhSHH induced cell proliferation and the
phosphorylation of PLCγ1 and ERK1/2 in both cell lines.
Treatment with U73122 decreased the rhSHH-induced
phosphorylation of PLCγ1 and ERK1/2 to sub-baseline
levels (Fig. 6e). Collectively, these data demonstrate that
autocrine SHH-mediated cell proliferation was at least par-
tially activated through the PLCγ1-ERK1/2 pathway.
Discussion
The functions of the SHH signaling pathway have been
previously explored in various types of human tumors,
including B-cell lymphoma [22], malignant pleural
mesothelioma [23], medulloblastoma [24, 25], pancre-
atic cancer [26, 27], prostate cancer [28, 29], lung cancer
[30, 31], basal cell carcinoma [13], and chronic myeloge-
neous leukemia [32]. However, this is the first study to
explore the role of autocrine SHH signaling in GC. In
the present study, SHH expression was detected in
freshly frozen GC tissues, and expression of SHH
mRNA and protein was higher in GC tissue compared
with that in matched adjacent noncancerous tissue.
Importantly, we observed that SHH concentration was
significantly increased in serum samples from GC pa-
tients, supporting a potential role as a GC biomarker
with diagnostic value. We demonstrated that SHH is se-
creted by GC cells and promotes cell proliferation in an
autocrine fashion through the PLCγ1-ERK1/2 signaling
pathway. In vitro, higher SHH expression was associated
with several tumor progression features and poorer OS
in GC.
It has been reported that SHH overexpression corre-
lates with the clinicopathologic characteristics and prog-
nosis of GC patients. Niu et al. [18] evaluated 113 cases
of GC and found that SHH overexpression correlated
with age, degree of tumor differentiation, T staging, and
N staging. Furthermore, SHH overexpression did not
significantly correlate with OS and DFS. However, Kim
et al. [19] found that patients at a lower disease stage
showed higher SHH expression, and SHH overexpres-
sion was associated with a favorable prognosis in GC pa-
tients. Interestingly, Yoo et al. [20] found that SHH
expression positively correlated with lymphatic metasta-
sis and poor prognosis. Interestingly, in this study,, we
Fig. 6 Autocrine SHH promotes cell proliferation through a PLCγ1-dependent pathway in GC cell lines. a Representative western blot demonstrat-
ing phosphorylation of PLCγ1 and ERK1/2 in AGS and SGC-7901 cells following Recombination Human SHH (rhSHH) treatment. b Western blot ex-
periments demonstrated that Condition Medium (CM) activated phosphorylation of PLCγ1 and ERK1/2 in AGS and SGC-7901 cells, with or
without SHH-neutralizing antibody (SHH-NA) treatment. c GC cell proliferation in response to the PLCγ1 inhibitor (U73122) in AGS cells. d GC cell
proliferation in response to the PLCγ1 inhibitor (U73122) in SGC-7901 cells. e After U73122 treatment, protein levels were analyzed using western
blot, with GAPDH used as a loading control. Mean ± SEM, t-test, *P < 0.05, **P < 0.01,***P < 0.001
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observed that higher expression of SHH was significantly
associated with advanced distant metastasis, and advanced
TNM staging. Lower expression of SHH was significantly
associated with advanced tumor invasion, increased lymph
node metastasis. Survival analysis demonstrated that pa-
tients with high SHH expression have a shorter survival
time compared with that of patients with low expression,
suggesting that SHH expression is an independent pre-
dictor of poor survival in GC patients.
Lian and colleagues firstly proposed the paracirne
manner of SHH signaling in stromal cells in prostate
cancer, and demonstrated that paracrine SHH signaling
could promote tumor growth [14]. Several studies also
comfired that parocrine SHH signaling affects the devel-
opment and differentiation of thymocyte and other cell
types [33–35]. Conversely, Rhim et al. reported that in-
hibition of SHH siganling accelerated tumor progression
in a mouse model of pancreatic adenocarcinoma, and
demonstrated that paracrine SHH signaling could act to
restrain, rather than promote tumor progression [36].
Additionally, the biological functions of autocrine SHH
signaling have been demonstrated in morphogenesis,
pathophysiologic processes, and tumorigenesis [37–39].
Liu et al [21]. reported that autocrine SHH signaling en-
hanced myeloma cell proliferation and protected cells
against chemotherapy-associated spontaneous and
stress-induced apoptosis. Similarly, in this study, we
confirmed that SHH protein could be secreted outoff
GC cells and into blood, and also autocrine SHH signal-
ing could promote cell proliferation.
Activation of SHH signaling correlates with that of the
insulin growth factor (IGF), PI3K-AKT, WNT, and
Notch pathways [40, 41]. SHH has been shown to regu-
late cell proliferation and differentiation through the
MAPK-ERK and PI3K-AKT signaling pathways [42]. In
addition, MAPK activity was shown to play an important
role in modulating SHH-mediated gene transcription in
astrocytes [43]. Ge et al. [44] demonstrated that SHH
signaling contributes to PFKFB3 activation via Smo and
p38 MAPK/MK2, causing accelerated glycolysis and cell
proliferation in breast cancer cells. We determined that
treating of cells with rhSHH and CM induced PLCγ1
and ERK1/2 phosphorylation. After treating cells with
U73122, an inhibitor of PLCγ1, rhSHH and CM did not
activate PLCγ1 and ERK1/2. These results strongly sug-
gest that autocrine SHH signaling promotes cell prolifer-
ation through the PLCγ1- ERK1/2 signaling pathways.
Conclusions
In conclusion, the present study demonstrated that SHH
overexpression is associated with poor GC survival. SHH
expression status could represent a useful prognostic indi-
cator and a potential therapeutic target for individualized
treatment. GC tissues secrete SHH into the tumor
microenvironment and eventually into the systemic circula-
tion. Secreted SHH stimulates cell proliferation via the
PLCγ1- ERK1/2 signaling pathway in an autocrine fashion.
Targeting SHH could provide a novel therapeutic strategy
for GC treatment, and SHH could represent a novel GC
biomarker.
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